Skip to content

Psychedelic-assisted therapy research published in 2025

Page 5 of 11: studies 81 to 100 of 219, newest first. Back to the psychedelic-assisted therapy overview

Studies

Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression

Journal of Psychopharmacology July 1, 2025 Ryan M Brudner, Erica Kaczmarek, Marc G Blainey et al. 3 citations

Background: Psilocybin-assisted psychotherapy (PAP) is a promising treatment for various psychiatric disorders. However, the exact biological and psychological mechanisms of action of PAP remain to be determined. Examining predictors of PAP outcomes may help identify necessary processes for positive treatment outcomes. Mystical experiences are considered a key aspect of the subjective effects...

Exploring psychedelic experiences among people who regularly use methamphetamine: Findings from an international survey.

Drug and Alcohol Dependence July 1, 2025 Dilara Bahceci, Krista J. Siefried, Maureen Steele et al.

Methamphetamine use disorder, associated with significant morbidity and mortality, has limited effective treatments. Psychedelic-assisted psychotherapy shows promise, but data on its safety and efficacy in this population are limited. This exploratory study describes the demographic, substance use, and mental health characteristics of people who used methamphetamine and psychedelics and the...

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

Medical Science Monitor June 30, 2025 Andrzej Silczuk, Robert Madejek, Tytus Koweszko et al. 4 citations

Psychedelics, derived from the Greek words "psyche" (soul) and "deloun" (revealing), are substances historically and currently considered "soul-revealing". Also termed hallucinogens due to their impact on sensory perception, they are further categorized into hallucinogens, such as lysergic acid diethylamide (LSD), psilocybin, and mescaline; entactogens or empathogens, such as...

DOI: 10.12659/msm.948302 (opens in new tab) Mental health Medline Psychotherapist Intensive care medicine

Psychedelic-Assisted Therapies for Psychosocial Symptoms in Cancer: A Systematic Review and Meta-Analysis

Current Oncology June 30, 2025 Haley D M Schuman, Chantal Savard, Raèf Mina et al. 9 citations

This systematic review and meta-analysis evaluates (1) the effectiveness of psychedelic-assisted therapy (PAT) using psilocybin and ketamine for psychosocial symptoms in adults with cancer, (2) contextualizes findings with non-randomized and exploratory studies of other psychedelics, and (3) examines the role of therapeutic frameworks in shaping outcomes. We searched PubMed, Cochrane Library,...

Exploring the integration of psychedelic-assisted therapy and digital mental health interventions in trauma recovery for underserved adults with high-functioning autism

Magna Scientia Advanced Research and Reviews June 28, 2025 Paul Okugo Imoh, Aderonke Ajiboye, Tahir Kolawole Balogun et al. 5 citations

Trauma-related disorders and substance use are disproportionately underdiagnosed and undertreated in individuals with High-Functioning Autism (Level 1 Autism Spectrum Disorder), particularly those in underserved or marginalized communities. Emerging evidence suggests that psychedelic-assisted therapies—including psilocybin, MDMA, and ketamine—offer promising outcomes in the treatment of...

DOI: 10.30574/msarr.2025.14.1.0079 (opens in new tab) Full text (opens in new tab) Psychological intervention Mental health Autism Clinical psychology +1

The Use, Role, and Function of Music During Psychedelic-Assisted Therapy (PAT) with Ayahuasca: A Scoping Review Protocol

Psychoactives June 25, 2025 Guillermo Escobar-Cornejo, Fernando P. Cárdenas, Diego Torres et al.

Objective: To provide a state of the art on the use, role, and function of music during psychedelic-assisted therapy (PAT) with ayahuasca. Introduction: Ayahuasca is a medicinal brew with psychoactive qualities used by indigenous communities throughout the Amazon region, and music is deemed crucial during ayahuasca experiences. In PAT, music forms part of the set and setting, but it lacks...

DOI: 10.3390/psychoactives4020009 (opens in new tab) Full text (opens in new tab) Psychedelic therapy DMT Dimethyltryptamine Psychedelic-assisted therapy pat Yagé +12

Natural Guardians of the Balkans: Entheogens in Indigenous Practices and Their Implications for Well-Being and Therapy

Psychoactives June 25, 2025 Lucija Vejmelka, Damir Gašpar

Psychedelic plants and fungi have been traditionally used in many cultures as part of ritual ceremonies and ancient medicinal treatments. In some regions, these psychoactive plants have already entered mainstream discourse through popular literature and art. Today, numerous academic and medical institutions are establishing dedicated departments to examine the benefits and risks of...

A Perspective for Enhancing the Supervision of Psychedelic-Assisted Therapy: Motivational-Interviewing-Enhanced Integration Supervision (MIE-IS)

Psychoactives June 25, 2025 Mitch Earleywine, Alyssa B. Oliva

While research on psychedelic-assisted therapy (PAT) continues to show promise, challenges in its clinical application persist. One relevant domain includes how supervision might enhance both client and trainee outcomes. Current data suggest that, despite supervisor reports and the enthusiasm of trainees, supervision accounts for extraordinarily little variance in treatment outcome. We propose...

DOI: 10.3390/psychoactives4020014 (opens in new tab) Full text (opens in new tab) Psychedelic-assisted therapy Clinical supervision Motivational interviewing Supervisory relationships +6

Assessing the Attitudes of Dutch Mental Health Care Professionals Toward Psychedelic-Assisted Psychotherapy: A Cross-Sectional Exploratory Study

Journal of Psychoactive Drugs June 23, 2025 Annika Wirsching, Erwin Krediet, Martijn H B Koolen et al. 4 citations

Psychedelic-assisted psychotherapy (PAP) constitutes a novel treatment paradigm in mental health care practice that is currently being evaluated for its clinical efficacy and safety. Insight into the attitudes of clinicians toward PAP remains crucial for its successful integration into mental health care. This cross-sectional survey explores the attitudes of Dutch mental health care...

DOI: 10.1080/02791072.2025.2508156 (opens in new tab) Cross-sectional study Mental health care Exploratory research Psychotherapist +1

Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial.

European Neuropsychopharmacology June 17, 2025 Isabel Wießner, Marcelo Falchi-Carvalho, Sophie Laborde et al. 7 citations

Vaporized N,N-Dimethyltryptamine (DMT) has a short duration and simple application, prompting this technique as a new approach for psychedelics' clinical use. Building on our initial dose-ascending studies and addressing potential confounding effects of dosing order, this study is the first to evaluate inhaled DMT in a randomized, placebo-controlled, double-blind design. Given DMT's therapeutic...

DOI: 10.1016/j.euroneuro.2025.06.002 (opens in new tab) Full text (opens in new tab) Psychedelic therapy N,N-Dimethyltryptamine Placebo-controlled study Psychedelics +17

Authenticity and Love Drugs: Insights from Psychedelic Therapy.

AJOB Neuroscience June 16, 2025 Owen Thomas, Francisca Silva

In "Prescription for Love: An Experimental Investigation of Laypeople's Relative Moral Disapproval of Love Drugs," Lantian, Boudesseul, and Cova (2024) explore the moral implications of hypothetical romantic love-enhancing biotechnological interventions. Their study reveals "love drugs" (LDs) are viewed as less acceptable than psychological therapy due to the perceived inauthenticity of the...

LSD Restores Synaptic Plasticity in VTA of Morphine-Treated Mice and Disrupts Morphine-Conditioned Place Preference.

bioRxiv : the preprint server for biology June 15, 2025 Michael Von Gunten, Tenna Russell, Isaac Stirland et al. preprint

Psychedelics are emerging as a promising treatment option for a range of neuropsychiatric disorders, including substance use disorders. One potential mechanism underlying their therapeutic benefits may involve a reversal of maladaptive plasticity induced by drug exposure. Here, we identify physiological, behavioral, and epigenetic impacts of lysergic acid diethylamide (LSD) on morphine-treated...

Synergistic behavioral and neuroplastic effects of psilocybin-NMDAR modulator administration

Translational Psychiatry June 13, 2025 Tom Ben-Tal, Ilana Pogodin, Alexander Botvinnik et al. 2 citations

The full therapeutic potential of serotonergic psychedelics (SP) in treating neuropsychiatric disorders, such as depression and schizophrenia, is limited by possible adverse effects, including perceptual disturbances and psychosis, which require administration in controlled clinical environments. This study investigates the synergistic benefits of combining psilocybin (PSIL) with...

DOI: 10.1038/s41398-025-03428-x (opens in new tab) Full text (opens in new tab) Psychedelic therapy Mental health treatment Neuroscience research Psilocybin studies +1

Pasifika healthcare professionals' perspectives on psychedelic-assisted therapy

Journal of Psychedelic Studies June 12, 2025 Musheerah Nuha, Lisa Reynolds, Jessee Fia’ali’i 2 citations

Abstract Background and aims In recent years, there has been increasing attention on the potential for psychedelic-assisted therapies to be used in healthcare. However, the turbulent history of psychedelics challenges its implementation and concerns about cultural safety, equity, and diversity in research remain unresolved. In Āotearoa New Zealand, Pasifika populations face significant health...

DOI: 10.1556/2054.2025.00413 (opens in new tab) Full text (opens in new tab) Health professionals Health care Nursing Medical education +1

From molecules to meaning: unpacking the antidepressant mechanisms of psychedelic drugs.

Expert Review of Clinical Pharmacology June 11, 2025 Victor Pablo Acero, Taylor A Flatt, Peter M. Gooch et al.

Psychedelic compounds are emerging treatments for depression, capable of producing rapid and lasting symptom reduction after 1-2 administrations in the context of psychotherapy - a stark contrast to traditional antidepressants. Despite promising outcomes, the mechanisms underlying psychedelics' reported antidepressant effects remain poorly understood and are often framed in fragmented ways....

A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.

Journal of Psychopharmacology June 10, 2025 Torsten Passie, Anja Loizaga-Velder, Alicia Danforth et al. 4 citations

The authors offer a model for curriculum for education and training in substance-assisted psychotherapy (SAP), that is, psychedelic, psycholytic, and entactogen/MDMA (3,4-methylenedioxymethamphetamine)-assisted psychotherapy, addressing both the detailed contents of training and the question of experiential training. All authors of this model have an abiding interest and extensive experience in...

DOI: 10.1177/02698811241282759 (opens in new tab) Full text (opens in new tab) Psychedelic therapy MDMA-Assisted Psychotherapy Education of therapists Psycholytic therapy +7

Reconnecting through dissociation: a 5-month follow-up case study on ketamine-assisted psychotherapy for anorexia nervosa.

Journal of Eating Disorders June 10, 2025 Camilla Lindvall Dahlgren, Elisabeth Tverrli, Lowan Han Stewart 3 citations

Ketamine, an N-methyl-D-aspartate receptor antagonist, has demonstrated rapid antidepressant effects at sub-anesthetic doses, making it a promising candidate for treatment-resistant mood disorders, anxiety, post-traumatic stress disorder, suicidality, and recently, eating disorders (EDs). However, its effects are transient, and ketamine-assisted psychotherapy (KAP) has emerged as a method to...

DOI: 10.1186/s40337-025-01313-y (opens in new tab) Full text (opens in new tab) Case report Dissociation Follow-up Ketamine-assisted psychotherapy +5

‘Equal-unblinding’ meta-analysis of psychedelic therapy vs. antidepressants for the treatment of depression

PsyArXiv June 9, 2025 3 citations preprint

Importance: Psychedelic-assisted therapy (PAT) trials have high levels of functional unblinding. This effect positively biases results when PAT trials are compared against truly blinded trials. Objective: This pre-registered meta-analysis investigated the comparative efficacy of PAT and open-label traditional antidepressants (tAD; such as SSRIs and SNRIs) for the treatment of major depression....

DOI: 10.31234/osf.io/vhs4a_v1 (opens in new tab) Psychedelic therapy Psychedelic treatment Psychedelics Hallucinogen therapy +14

Investing in Group Psychedelic Therapy for Latinx Immigrants.

Journal of immigrant and minority health June 9, 2025 Juliana Zambrano, Fernando Espí Forcén, Jose Hidalgo et al.

Despite increasing interest in psychedelic-assisted therapies (PAT), there remains a critical gap in extending these treatments to marginalized and vulnerable populations, including Latinx immigrants. This underrepresentation in both research and clinical practice exacerbates disparities in mental health care access for racial and ethnic minorities, who already face systemic barriers. The...

DOI: 10.1007/s10903-025-01702-0 (opens in new tab) Full text (opens in new tab) Immigrant mental health Psychedelic assisted therapy Psychedelics Hallucinogen therapy +5

Patient-therapist relationship in psychedelic-assisted therapy: Implications for future real-world settings.

General Hospital Psychiatry June 6, 2025 Daniel Villiger 4 citations

The view that the use of serotonergic psychedelics in mental health care should always be psychotherapeutically embedded has recently been questioned. One argument against this model concerns the high costs it entails, which could limit the accessibility of psychedelic-assisted therapy (PAT)-a concern likely to gain traction if PAT is officially approved in the future. This paper analyzes the...